-
STARTRADER Raises Lloyd's of London Client Fund Insurance to USD 30 Million in Aggregate
-
Indonesia charges train driver over crash that killed 16 women
-
North Korean DMZ landmine blasts 'violation of armistice': Seoul
-
Ruthless An makes history to retain Asian Games badminton crown
-
Sabalenka 'fresh' for first tournament since losing No.1 spot
-
Australian central bank lifts key interest rate to 15-year high
-
Myanmar airstrike death toll rises to 50: aid workers
-
Polo makes landfall in Mexico as Category 3 hurricane
-
North Korean DMZ landmine blast 'violation of armistice'
-
South Korea team latest to be bussed to wrong Asian Games venue
-
South Korea volleyball team latest to be bussed to wrong Games venue
-
Bears thrash Eagles 27-7 as third-string QB Keenum shines
-
Malaysia starts sending Myanmar migrants home
-
All Blacks name veteran Taylor captain as Mo'unga seizes 10 jersey
-
8.3 mn refugees at risk due to 'severe' funding cuts: UN
-
Race against time as Asian Games cricket quarter-finals washed out
-
Stocks drop and oil rises as Hormuz hopes fade
-
India turns to corals and seagrass to shield against rising seas
-
OpenAI cancels release of newest model due to safety concerns
-
Manchester City's Premier League charges: What comes next?
-
AI bosses head to White House as safety pressure builds
-
Brazil's cellphone crime: a security nightmare in every pocket
-
Batista sacked as Costa Rica coach after six months
-
Russia pummels Kyiv in latest deadly attack
-
Flooding, power cuts and evacuations as Hurricane Polo slams Mexico
-
fiskaltrust launches e-invoicing across Europe
-
Yokogawa Brings Publication-Backed Validation from More Than 60,000 Scientific Publications to its CSU Spinning Disk Confocal Systems with Bioz
-
Star Copper Advances Western Extension Drilling at Star Main
-
Genflow Biosciences PLC Announces Half-year Financial Report
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 29
-
Akkodis and Biolevate Partner to Accelerate AI-Powered Scientific, Regulatory and Technical Documentation in Highly Regulated Industries
-
NFL Giants obtain QB McCarthy from Vikings
-
Dodgers eye three-peat, Red Sox face Yankees as MLB playoffs begin
-
Deal for evicted Spanish pensioner as PM seeks new housing law
-
Certification of Boeing 737 MAX delayed by software bug
-
Clippers apologize, warn fans of 'challenges' after Leonard scandal
-
Celine Dion wows Paris Fashion Week with surprise gig
-
Turkish comedian convicted for Erdogan 'insult' freed pending appeal
-
AMD buys firm founded by AI 'godmother' Fei-Fei Li
-
Trump announces 'biggest' US steel plant in battleground Iowa
-
Italy rebound in Turkey as France win late in Belgium
-
Olise wonder strike gives Zidane's France win in Belgium
-
Pope says concerns about AI 'should be taken seriously'
-
US stocks fall, bond yields rise as Middle East war drags on
-
Hurricanes to hoist title banner as NHL season begins
-
Trump denies offering to sell arms to China's Xi
-
Justice Alito steps aside from major US climate case
-
Wemby ready for NBA Spurs to move rivals in climb to top
-
Willis happy with England exile after retains Top 14 player award
-
Ukraine to postpone some spending amid delays in aid: PM
Revive Therapeutics Announces Proposed Shares for Debt Settlement
TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deemed price of $0.05 per Settlement Share to settle an aggregate of $61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").
The Settlement Shares will be issued in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. Completion of the Debt Settlement remains subject to certain conditions, including receipt of all necessary regulatory approvals, including approval of the CSE.
The Debt Settlement is expected to close no earlier than five business days from the date of this news release and remains subject to CSE acceptance
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1-888-901-0036
Email: [email protected]
Website: www.revivethera.com
SOURCE: Revive Therapeutics Ltd.
View the original press release on ACCESS Newswire
D.Moore--AMWN